Various gene therapies are currently in development, including those aimed at myosin-binding protein C3 (MYBPC3)-related cardiomyopathy (NCT05836259) and the use of antisense oligonucleotides for PLN-R14del cardiomyopathy.34 This evidence concerns the gene PLN and cardiomyopathy.